

# BACKGROUND

- > Major depressive disorder (MDD) is a com illness with nearly one in five people exper episode at some point in their lifetime
- Introduction of novel and efficacious agent treatment of depression has been relatively
- Psilocybin has become an agent of interest treatment of depression with recent studies supporting safety and efficacy

## OBJECTIVE

- Examine the significance and potential of as an agent in the treatment of depression
- Describe therapeutic properties and review research

## **EXISTING THERAPY**

- > The pathophysiology of MDD remains unc
- > The monoamine hypothesis is the most wid accepted model that has been proposed
- $\blacktriangleright$  The development of agents for the treatmer depression has largely followed this hypoth explanation of observed efficacy
- > Mechanism refinement in newer antidepres helped improve tolerability
- Side effect burden remains a concern with antidepressants including SSRIs, which are widely prescribed class
- $\succ$  Up to 43% of patients with MDD have stop an antidepressant due to side effects
- > Onset of clinical effect and response can reweeks to months

#### **Drug Development**

- > A general lack of novel agents for the treat depression can be attributed to:
  - Costly late-stage trial failures
  - Limited understanding of the biological mental disorders
- $\triangleright$  Esketamine was approved for use in 2019 as an adjunct therapy in treatment-resistant depression

## **Psilocybin in the Treatment of Depression** Ben Hoelscher, PharmD Candidate Ronald Worthington, PhD

#### Efficacy

nmon criencing an ts for the y stagnant t in the	<ul> <li>Around two-thirds of patients init not have remission in symptoms</li> <li>Relapse is seen within 6-12 mont</li> <li>Number needed to treat (NNT) is</li> <li>NNT is conventionally used v</li> <li>Therapeutic alliance and experience of antidepressant R</li> <li>These non-specific factors are response observed in antidepressant</li> <li>Estimated NNT of placebo-control</li> <li>Mild-to-moderate: 16, Severe</li> </ul>
psilocybin	PSIL
	<ul> <li>Compound found in a variety of</li> <li>Psychoactive compounds psilocy</li> </ul>
	<ul><li>psilocin were identified in 1958 and 7</li><li>Clinical studies in the 60's and 7</li></ul>
clear	<ul> <li>produced by psilocybin</li> <li>Psychedelic use became associat to the Vietnam war</li> </ul>
	<ul> <li>Oregon is developing a framewo</li> <li>Qualified facilitators with approp</li> </ul>
ssants has	P Binds with high affinity as an ag
e the most	<ul> <li>receptor and lacks affinity for the</li> <li>Agonism at the 5-HT2A receptor neurotrophic factor (BDNF) and</li> </ul>
pped taking	Cortical layer V
equire	-1 Glutamate NMDAR release
ment of	AMPAR
l basis of	€ BDNF

Ž

its initially treated with an antidepressant will

months in approximately 50% of patients NT) is a common metric of drug efficacy used with the control condition being placebo l expectancy are present in the placebo sant RCTs for the treatment of MDD ors are responsible for an estimated 60-80% of tidepressant RCTs

controlled antidepressant trials by severity: Severe: 11, Very-severe: 4

## SILOCYBIN

### History

ety of mushrooms

silocybin and the major active metabolite

1958 at Sandoz laboratories then marketed

and 70's found an altered state of consciousness

sociated with cultural rebellion and opposition

### **Current Legislation**


Psilocin/

LSD/DMT

nework for medical psilocybin administration appropriate training will deliver therapy **Properties** 

an agonist or partial agonist at the 5-HT2A for the dopamine D2 receptor

ceptor is thought to increase brain-derived ) and produce the "dream-like" effect



## SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE SCHOOL OF PHARMACY

## **RECENT RESEARCH**

### **Proposed Mechanism of Action (MOA)**

➢ fMRI has revealed decreased integrity of the default mode network (DMN) during psilocybin administration > Increases in cortical neuroplasticity with long-term changes in network functionality have been observed

#### Safety

Psilocybin can be safely administered under medical supervision in patients with no history of or predisposition to psychotic disorders. No dependency observed.

#### Outcomes

> Available research has suggested rapid and long-lasting positive effects of psilocybin in the treatment of depression when administered in a supportive environment

Trial of Psilocybin versus Escitalopram for Depression Randomized double-blind phase 2 clinical trial (n=59) Psilocybin arm: 25 mg psiliocybin 3 weeks apart and 6 weeks of daily placebo (n=30)

Escitalopram arm: 6 weeks of once daily escitalopram and 1 mg psilocybin 3 weeks apart (n=29)

Primary efficacy outcome: change from baseline in the QIDS-SR 16: Psilocybin -8.0  $\pm$  1.0 points, escitalopram -6.0 + 1.0 (95% CI, -5.0 to 0.9)

Secondary outcomes included measures of anxiety, anhedonia, experiential avoidance, sexual dysfunction, emotional intensity, and well-being among others > All secondary outcomes favored psilocybin

## CONCLUSION

> Any agents with potential for long-lasting efficacy and an acceptable safety profile should be investigated in MDD Safety and regulatory issues will need to be addressed through thorough screening and protocol implementation

> Approval of psilocybin in the treatment of depression would introduce an entirely novel MOA to psychiatry > Psilocybin research has produced novel outcome measures not traditionally seen in antidepressant RCTs

> Adoption of a treatment modality requiring a behavioral component such as psilocybin could result in a shift of the existing mental health landscape